| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 14877 | 2008 |
| Management of Hepatocellular Carcinoma: An UpdateΔσ J Bruix, M Sherman Hepatology 53 (3), 1020-1022, 2011 | 9779 | 2011 |
| Management of hepatocellular carcinoma J Bruix, M Sherman Hepatology 42 (5), 1208-1236, 2005 | 7471 | 2005 |
| Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference J Bruix, M Sherman, JM Llovet, M Beaugrand, R Lencioni, AK Burroughs, ... Journal of hepatology 35 (3), 421-430, 2001 | 5145 | 2001 |
| Prognosis of hepatocellular carcinoma: the BCLC staging classification JM Llovet, C Brú, J Bruix Seminars in liver disease 19 (03), 329-338, 1999 | 4467 | 1999 |
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial JM Llovet, MI Real, X Montaña, R Planas, S Coll, J Aponte, C Ayuso, ... The Lancet 359 (9319), 1734-1739, 2002 | 3854 | 2002 |
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival JM Llovet, J Bruix Hepatology 37 (2), 429-442, 2003 | 3796 | 2003 |
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ... The Lancet 389 (10064), 56-66, 2017 | 3470 | 2017 |
| Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis V Mazzaferro, JM Llovet, R Miceli, S Bhoori, M Schiavo, L Mariani, ... The lancet oncology 10 (1), 35-43, 2009 | 2160 | 2009 |
| Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation JM Llovet, J Fuster, J Bruix Hepatology 30 (6), 1434-1440, 1999 | 2049 | 1999 |
| Design and endpoints of clinical trials in hepatocellular carcinoma JM Llovet, AM Di Bisceglie, J Bruix, BS Kramer, R Lencioni, AX Zhu, ... Journal of the National Cancer Institute 100 (10), 698-711, 2008 | 2043 | 2008 |
| BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update M Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ... Journal of hepatology 76 (3), 681-693, 2022 | 1879 | 2022 |
| Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma J Bruix, M Reig, M Sherman Gastroenterology 150 (4), 835-853, 2016 | 1755 | 2016 |
| Cholangiocarcinoma 2020: the next horizon in mechanisms and management JM Banales, JJG Marin, A Lamarca, PM Rodrigues, SA Khan, LR Roberts, ... Nature reviews Gastroenterology & hepatology 17 (9), 557-588, 2020 | 1497 | 2020 |
| Hepatocellular carcinoma: clinical frontiers and perspectives J Bruix, GJ Gores, V Mazzaferro Gut 63 (5), 844-855, 2014 | 1471 | 2014 |
| Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials JM Llovet, J Bustamante, A Castells, R Vilana, MDC Ayuso, M Sala, C Brú, ... Hepatology 29 (1), 62-67, 1999 | 1467 | 1999 |
| Prognostic prediction and treatment strategy in hepatocellular carcinoma J Bruix, JM Llovet Hepatology 35 (3), 519-524, 2002 | 1426 | 2002 |
| Gene expression in fixed tissues and outcome in hepatocellular carcinoma Y Hoshida, A Villanueva, M Kobayashi, J Peix, DY Chiang, A Camargo, ... New England Journal of Medicine 359 (19), 1995-2004, 2008 | 1330 | 2008 |
| Current strategy for staging and treatment: the BCLC update and future prospects A Forner, ME Reig, CR de Lope, J Bruix Seminars in liver disease 30 (01), 061-074, 2010 | 1317 | 2010 |
| Molecular targeted therapies in hepatocellular carcinoma JM Llovet, J Bruix Hepatology 48 (4), 1312-1327, 2008 | 1251 | 2008 |
